Kian Fan Chung (National Heart & Lung Institute, Imperial College London, and Royal Brompton & Harefield NHS Trust, London) shares his expert insight on exciting advances in the treatment of asthma.
Questions
1. What do you consider the most exciting advances in the treatment of asthma in the last year? (0:12)
2. What has been the impact of phenotyping on the treatment of severe asthma? (0:51)
3. How have the new monoclonal antibodies fitted into the treatment paradigm for severe asthma? (1:33)
4. What are the limitations of these monoclonal antibodies? (2:20)
5. What other promising agents are in clinical development? (3:06)
Speaker disclosure: Kian Fan Chung has been renumerated for participation on advisory boards of AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, 4D Pharma, Merck Sharp & Dohme, and Menlo Therapeutics discussing new therapies for respiratory conditions.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
